Cantex Pharmaceuticals
CompanyUnited States
Cantex Pharmaceuticals develops one asset, in phase 1 (azeliragon in glioblastoma). Mostly small molecule acting on AGER; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 2
- Trials
- 1
- Signal
Pipeline
1Inhibits the receptor for advanced glycation end products, suppressing inflammatory signaling.
Phase 1, Small molecule, AGER, glioblastoma
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials9
- Signals2
- Similar companies6